Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Brian Moore who wrote (15150)	2/19/1998 5:50:00 PM
From: Henry Niman	Respond to of 32384

Brian, It looks like I never responded to this post. Much of the data on LGND's clinical trials can be found at home.att.net LGND's most advanced drugs that were developed in house are the retinoid/rexinoids. There are 5 formulations currently in the clinic (oral and topical Panretin and Targretn as well as oral LGD1550). Two other compounds (Droloxifene and CP-366,156) are also in the clinic. These trials are being run by PFE and LGND will get milestone and royalty payments. This year is slated to be a banner year for new compounds. Most if not all will be introduced by LGND's partners, at no cost to LGND. Again LGND will get milestone and royalty payments. LLY is slated to move Targretin into US diabetes trials. They are also supposed to file an IND for one of LGND's second generation rexinoids (LGD1268 or LGD1324). AGN is also slated to enter a couple of compounds into the clinic (an anti-retinoid and a second generation rexinoid). AHP is slated to file an IND this quarter for its designer estrogen, TSE424. ABT is also slated to file an IND for a gluccocorticoid receptor modulator and GLX is slated to file for an LDL modulator. All of the above (except the anti-retinoid) target multi-billion dollar markets (Diabetes, Osteoporosis, Atherosclerosis, Inflammation). In the short term, clinicals center on LGND's in-house products, oral and topical Panretin and Targretin. Panretin is the most advanced. Clinical testing on Kaposi's Sarcoma has been completed and an IND is slated for this quarter. The compound should be on pharmacy shelves this year. There are no approved topical treatments for KS. Targretin oral and topical are finishing up Phase III trials for Cutaneous T-Cell Lymphoma. Phase I/II results have been very strong and INDs are slated for later this year. Both products should be for sale next year. Oral Panretin is in Phase II/III trials for Acute Promyelocytic Leukemia (now just in Europe) and heading for Phase III trails for Kaposi's Sarcoma. NDAs are slated for next year. LGD1550 oral should be finishing up Phase I trails and Phase II trials are being planned. Thus LGND is marching toward profitability which is projected for 1999.